1,780 results on '"Büchner T"'
Search Results
2. Treatment of Older Patients with Acute Myeloid Leukemia (AML)
3. Randomized Comparison of Sequential High-Dose Cytosine Arabinoside and Idarubicin (S-HAI) with or without Chemo-Modulation by Fludarabine in Refractory and Relapsed Acute Myeloid Leukemia
4. Including Quality of Life as an Important End Point in Evaluating Intensive and Prolonged Treatment for Acute Myeloid Leukemia (AML)
5. The Impact of Treatment on the Outcome of Cytogenetic Subgroups in Acute Myeloid Leukemia -Results of the German AML Cooperative Group
6. Multivariate Analysis of Prognostic Factors in Patients with Refractory and Relapsed Acute Myeloid Leukemia Undergoing Sequential High-Dose Cytosine Arabinoside and Mitoxantrone (S-HAM) Salvage Therapy: Significance of Cytogenetic Abnormalities
7. Early Empiric Antifungal Treatment of Infections in Neutropenic Patients with Hematological Malignancies Comparing Fluconazole with Amphotericin B and 5-Flucytosine
8. Phase I Study of Liposomal Daunorubicin (DaunoXome) in Relapsed and Refractory Acute Myeloid Leukemia
9. Modulation of AraC by Fludarabine: Results of Salvage Therapy by AMLCG
10. RT-PCR in Diagnostics and Monitoring of Acute Myeloid
11. MLL-Duplications are Rare and Associated with Poor Prognosis in Acute Myeloid Leukemia
12. Although Patients with AML and Complex Aberrant Karyotype Can be Subdivided Into Different Subtypes by Cytogenetics, Prognosis is Equally Poor
13. Transforming Activity of Flt3 in 32D Cells
14. Evidence of Angiogenesis in Acute Myeloid Leukemia
15. Hematopoietic Growth Factors: Supportive and Priming Effects in AML
16. Growth Factors in AML: Updates
17. Chemotherapy for Acute Myeloid Leukemia: the State of the Art and the Contribution of Idarubicin
18. Detection of Minimal Residual Disease in Cytogenetically Defined Prognostic Subgroups of AML
19. Cytomorphology and Clinical Outcome in 80 Patients with AML M4Eo and Inversion 16
20. Correlation of Deoxycytidine Deaminase, Thymidine Kinase and Polymerase Alpha Activity and Deoxycytidine Deaminase Gene Expression In Vivo with Clinical Response to TAD-9+GM-CSF Induction Therapy in Acute Myeloid Leukemia
21. Characterization of Normal and Leukemic Lymphohematopoietic Precursor Cells by Three-Color Flow Cytometry and Detection of Clone-Specific Leukemia-Associated T-Cell Receptor δ Rearrangements
22. GM-CSF Dose Response Curves in Priming of AML Progenitors for Ara-C
23. Different Potential of G-CSF, GM-CSF, and pIXY in Priming of Myeloid Leukemic Progenitors for Ara-C
24. Quality of Life in Patients with Acute Myeloid Leukemia - A Longitudinal Study
25. Mediators in Sepsis and Septic Shock
26. Prognostic Value of Dysmyelopoiesis in 128 Patients with De Novo Acute Myeloid Leukemia
27. Preliminary Results of a Placebo-Controlled, Double-Blind Trial Evaluating Sequential HD-AraC/Mitoxantrone Induction Chemotherapy with or Without Granulocyte-Macrophage Colony-Stimulating Factor in Patients with High-Risk Myelodysplastic Syndromes
28. Methods to Detect Prognostic Factors in Acute Myeloid Leukemia
29. Intensified Therapy of Acute Myeloid Leukemia: Results of the German AML Cooperative Group
30. Early Empiric Antifungal Treatment of Infections in Neutropenic Patients Comparing Fluconazole with Amphotericin B/5-Flucytosine
31. Fluconazole Prophylaxis of Invasive Fungal Infections During Intensive Chemotherapy for Relapsed Acute Myeloid Leukemia: Interim Analysis of a Randomized Multicenter Trial
32. Fifty-nine Cases of Acute Myeloid Leukemia with Inversion inv(16) (p13q22): Do Additional Chromosomal Aberrations Influence Prognosis?
33. Hematopoietic Recovery and Priming — Therapeutic Effects of GM-CSF in the Treatment of AML
34. Hematologic and Therapeutic Effects of High-Dose AraC/Mitoxantrone (HAM) in the Induction Treatment of Patients with Newly Diagnosed AML. A Trial by AML Cooperative Group
35. Akute myeloische Leukämie (AML)
36. Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (⩾60 years)
37. Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia
38. Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia
39. Anämien
40. Modulation of Intracellular Ara-C Metabolism in AML Blasts by GM-CSF
41. Effects on Ara-C Cytotoxicity for AML Colony Forming Cells By Priming With rhGM-CSF and rhIL-3 In Vitro and In Vivo
42. GM-CSF in Chemotherapy for Newly Diagnosed AML: Multiple Course Priming and Longterm Administration Compared to Chemotherapy Alone
43. Significance of Lineage-Associated Transcripts of TdT and ETS1 for Detection of Leukemic Cells
44. Characterization of Clonal Gene Rearrangements for the Detection of Residual Leukemic Disease in Acute Lymphoblastic Leukemia
45. Prospective Study on the Clinical Relevance of Residual Disease in Patients with Acute Myeloid Leukemia in Complete Remission
46. Chemotherapy Intensity and Long-Term Outcome in AML
47. Clinical Aspects of Acute Myelogenous Leukemias of the FAB-Types M3 and M4Eo
48. Heterogeneity in the Stem Cell Compartment of Newly Diagnosed Acute Myeloid Leukemia Analyzed by 4-Colour Immunofluorescence
49. Biology Oriented Investigation of Treatment Strategies for Acute Myeloid Leukemia (AML): The AMLCG Approach
50. FS-HAI for Relapsed AML
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.